Mr. Bill Adams reports

NERVGEN PHARMA ANNOUNCES FILING OF FORM F-10 REGISTRATION STATEMENT WITH THE SEC UNDER MJDS

Nervgen Pharma Corp. has filed a registration statement on Form F-10 with the U.S. Securities and Exchange Commission (SEC) in accordance with the multijurisdictional disclosure system established between Canada and the United States.

The registration statement filed with the SEC has not yet become effective. No securities may be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under applicable securities laws. Management believes the filing of this registration statement provides flexibility to pursue various strategic initiatives in accordance with the company's growth strategy.

The registration statement contains important detailed information about the company. A copy of the registration statement is available on EDGAR. Copies may also be obtained from the company at Suite 112, 970 Burrard St., Unit 1290, Vancouver, B.C., V6Z 2R4.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. The company is evaluating the clinical efficacy of its first-in-class and potential best-in-class lead candidate, NVG-291, in the phase 1b/2a Connect SCI study in spinal cord injury.

We seek Safe Harbor.